A group LED by the Department of Neurosurgery, Brain Research Institute, Niigata University, Has Succeded in the Diagnosis of Leptomeningeal Disease in Difuse Midline Gliomas by Detecting s from circulating tumor dna of cerebrospinal fluid taken from these patients.

The work is Published in the journey Pediatric blood & cancer on January 9, 2025.

In Two Patients, Leptomeningeal Disease Was Diagnosed Earlier Than With Traditional Methods Such as MRI and Cerebrospinal Fluid Cytology. In one patient, long term survival after the diagnosis of leptomeningeal disease by early and aggressive intervention include Surgery, Radiation, Radiation, and intrarathecal delivery of ChemoticC al.

A Team LED by Dr. Manabu Natsudea used Droplet Digital PCR, A Highly Sensitive PCR System, to Detect Trace Amounts of Circulating Tumor DNA from the Serebrospinal Fluid of These PATENTS.

“We found that detecting circulating tumor dna in the cerebrospinal fluid of Diffuse Midline Glioma Patients WAS More Difability Than Other Brain Tumor Patients Such as Primary Center Lastoma, “Explains Dr. Natsudea.

“However, when we were able to detect mutant tumor dna, often the tumor had alredy spread to the cerebrospinal fluid, causing leptomeningeal disease. FFuse Midline gliomas can improve survival. “